Cherry Creek Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Cherry Creek Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$217K	Buy	70,536 +3,859	+6%	+$14.9K	0.09%	111
2025 Q4	$273K	Sell	66,677 -104	-0.2%	-$515	0.12%	90
2025 Q3	$326K	Buy	66,781 +2,649	+4%	+$13.9K	0.14%	87
2025 Q2	$325K	Buy	64,132 +535	+0.8%	+$2.63K	0.15%	85
2025 Q1	$336K	Buy	63,597 +1,470	+2%	+$10.7K	0.18%	82
2024 Q4	$420K	Buy	62,127 +4,787	+8%	+$32.2K	0.21%	67
2024 Q3	$378K	Sell	57,340 -35,998	-39%	-$258K	0.2%	70
2024 Q2	$700K	Buy	93,338 +35,782	+62%	+$312K	0.37%	45
2024 Q1	$574K	Buy	57,556 +39,703	+222%	+$442K	0.31%	52
2023 Q4	$176K	Buy	+17,853	New	+$127K	0.11%	96

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cherry Creek Investment Advisors's RXRX Position: Q1 2026 in Review

Cherry Creek Investment Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 5.8% in Q1 2026, buying an estimated $14.9K and bringing the position to 70,536 shares worth $217K. The position accounts for 0.09% of the portfolio, ranked #111.

Cherry Creek Investment Advisors first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $700K in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Cherry Creek Investment Advisors held 70,536 shares of Recursion Pharmaceuticals worth $217K as of Q1 2026.
Cherry Creek Investment Advisors bought 3,859 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14.9K.
Recursion Pharmaceuticals made up 0.09% of Cherry Creek Investment Advisors's portfolio in Q1 2026, its #111 holding.
Cherry Creek Investment Advisors first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Cherry Creek Investment Advisors's Recursion Pharmaceuticals position peaked at $700K in Q2 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Cherry Creek Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.